Published in Oncogenesis on November 26, 2012
Cytoprotection "gone astray": Nrf2 and its role in cancer. Onco Targets Ther (2014) 1.00
c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis (2014) 0.82
Lipoxins: nature's way to resolve inflammation. J Inflamm Res (2015) 0.80
Interaction between NFATc2 and the transcription factor Sp1 in pancreatic carcinoma cells PaTu 8988t. BMC Mol Biol (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Pancreatic cancer. N Engl J Med (2010) 13.88
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Pancreatic cancer. Lancet (2011) 8.54
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem (2009) 5.80
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci (2009) 4.50
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75
Dual roles of Nrf2 in cancer. Pharmacol Res (2008) 3.41
Targeting the ubiquitin system in cancer therapy. Nature (2009) 3.27
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis (2008) 3.19
The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol (2002) 3.05
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene (2003) 2.96
miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res (2010) 2.75
NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut (2008) 2.36
When NRF2 talks, who's listening? Antioxid Redox Signal (2010) 2.32
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol (2010) 2.27
Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol (2008) 2.21
NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer (2009) 2.18
Ras activity levels control the development of pancreatic diseases. Gastroenterology (2009) 2.17
Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res (2011) 2.14
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res (2010) 2.14
Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res (2007) 2.10
Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J (2006) 2.06
Nrf2 as a novel molecular target for chemoprevention. Cancer Lett (2004) 1.95
A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res (2009) 1.87
The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets (2010) 1.85
Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer (2003) 1.80
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun (2007) 1.79
High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res (2010) 1.70
Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal (2010) 1.64
Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer (2010) 1.62
Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol (2008) 1.60
Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology (2002) 1.57
Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun (2008) 1.56
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene (2006) 1.55
miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem (2011) 1.50
Inflammation and pancreatic ductal adenocarcinoma: a potential scenario for novel drug targets. JOP (2010) 1.48
NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology (2009) 1.47
Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology (2005) 1.47
Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev (2003) 1.46
Nrf2-dependent induction of proteasome and Pa28αβ regulator are required for adaptation to oxidative stress. J Biol Chem (2012) 1.46
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood (2006) 1.43
Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem (2003) 1.42
NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res (2011) 1.41
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res (2010) 1.40
Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci U S A (2007) 1.40
Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs (2009) 1.39
Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res (2010) 1.38
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer (2011) 1.38
Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res (2008) 1.37
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol (2010) 1.37
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res (2009) 1.35
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst (2011) 1.35
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene (2009) 1.32
Calcineurin as a multifunctional regulator. J Biochem (2002) 1.29
Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway. Cell Signal (2011) 1.28
The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle (2007) 1.27
Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer (2008) 1.26
The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget (2011) 1.25
Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med (2008) 1.24
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem (2001) 1.23
Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med (2011) 1.23
Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett (2010) 1.22
Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther (2010) 1.21
Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer (2011) 1.21
Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur J Cancer (2009) 1.20
Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res (2006) 1.18
Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res (2002) 1.17
Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett (2011) 1.17
NRF2, cancer and calorie restriction. Oncogene (2010) 1.17
Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann N Y Acad Sci (2011) 1.16
Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cell Signal (2010) 1.16
Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol (2012) 1.14
3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res (2009) 1.14
Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylase. J Biol Chem (2009) 1.13
Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell (2011) 1.12
Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett (2009) 1.11
Targeting apoptosis pathways in pancreatic cancer. Cancer Lett (2010) 1.11
Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci (2008) 1.11
CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J (2005) 1.11
CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene (2001) 1.10
Keap1: one stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL. Cancer Lett (2012) 1.09
Molecular basis of traditional Chinese medicine in cancer chemoprevention. Curr Drug Discov Technol (2010) 1.08
Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas (2010) 1.08
Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res (2009) 1.07
An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med (2012) 1.06
Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci (2011) 1.04
Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology (2011) 1.04
Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer (2003) 1.03
Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett (2010) 1.03
A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets (2011) 1.03
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol (2004) 2.70
Identification of and spatio-temporal differences between microbial assemblages from two neighboring sulfurous lakes: comparison by microscopy and denaturing gradient gel electrophoresis. Appl Environ Microbiol (2000) 2.51
[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr (1974) 2.50
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene (2006) 2.36
Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J (1997) 2.33
Influence of lipid/peptide hydrophobic mismatch on the thickness of diacylphosphatidylcholine bilayers. A 2H NMR and ESR study using designed transmembrane alpha-helical peptides and gramicidin A. Biochemistry (1998) 2.07
Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol (1986) 1.83
Validity of western immunoblot band patterns in the serodiagnosis of Lyme borreliosis. J Clin Microbiol (1991) 1.79
Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol (1994) 1.78
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Necrotizing lymphadenitis: Kikuchi--Fujimoto disease alias lupus lymphadenitis? Lupus (2009) 1.67
Immunochemical characterization and quantitative distribution of pancreatic stone protein in sera and pancreatic secretions in pancreatic disorders. Gastroenterology (1990) 1.60
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res (1996) 1.59
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene (2000) 1.56
Exploring the genetic link between RLS and ADHD. J Psychiatr Res (2009) 1.55
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene (2006) 1.55
Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics (2001) 1.53
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46
Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res (2001) 1.44
[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint]. Zentralbl Chir (1995) 1.44
Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia (2010) 1.41
Systemic effects and side effects of interstitial techniques used in liver tissue. J Am Coll Surg (1999) 1.39
Familial clustering of infantile cirrhosis in Northern Germany: A clue to the etiology of idiopathic copper toxicosis. J Pediatr (1999) 1.39
Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer (1994) 1.39
Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res (1997) 1.36
Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry (2010) 1.33
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene (2009) 1.32
Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol (2007) 1.32
Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept (2001) 1.30
A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. Mol Psychiatry (2006) 1.29
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res (1998) 1.28
The response of the microbial community of marine sediments to organic carbon input under anaerobic conditions. Syst Appl Microbiol (1999) 1.28
Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology (2004) 1.28
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene (2006) 1.27
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer (2003) 1.24
Role of Candida albicans in granulomatous tissue reactions. II. In vivo degradation of C. albicans in hepatic macrophages of mice. J Infect Dis (1977) 1.23
The beta-peptide hairpin in solution: conformational study of a beta-hexapeptide in methanol by NMR spectroscopy and MD simulation. J Am Chem Soc (2001) 1.22
Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells. Oncogene (2001) 1.22
Solid-state NMR determination of the secondary structure of Samia cynthia ricini silk. Nature (2000) 1.21
The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer (1996) 1.21
Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol (1990) 1.20
Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A (1993) 1.20
Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol (1998) 1.18
Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q13.1 and 14q12. Mol Psychiatry (2008) 1.18
Impulsive terahertz radiation with high electric fields from an amplifier-driven large-area photoconductive antenna. Opt Express (2010) 1.17
DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene (1999) 1.13
Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment. Eur Respir J (1998) 1.13
ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer (2004) 1.11
European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history. Digestion (1985) 1.11
CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene (2001) 1.10
FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun (2001) 1.10
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci (2001) 1.10
Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry (2005) 1.09
Ultrafast transient generation of spin-density-wave order in the normal state of BaFe2As2 driven by coherent lattice vibrations. Nat Mater (2012) 1.09
TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer (2011) 1.07
NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther (2002) 1.07
Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia (2006) 1.06
Dynamics of photoinduced charge-density-wave to metal phase transition in K0.3MoO3. Phys Rev Lett (2009) 1.05
Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology (1996) 1.05
Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med (1997) 1.05
Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg (1998) 1.04
Is there still a need for living-related liver transplantation in children? Ann Surg (2001) 1.04
Animal experimental studies on chronic granulomatous inflammation and T-lymphocyte-system. Beitr Pathol (1975) 1.03
Role of Candida albicans in granulomatous tissue reactions. I. In vitro degradation of C. albicans and immunospecificity of split products. J Infect Dis (1977) 1.03
NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res (2008) 1.01
Does treatment of varicocele improve male fertility? results of the 'Deutsche Varikozelenstudie', a multicentre study of 14 collaborating centres. Andrologia (2002) 1.01
Large quantitative effect of melanocortin-4 receptor gene mutations on body mass index. J Med Genet (2004) 1.01
In vivo studies on the incorporation of microinjected acidic proteins of the large ribosomal subunit from Escherichia coli and artermia salina into oocyte ribosomes from Xenopus laevis. Biochemistry (1979) 1.00
Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene (2007) 0.99
Prenatal diagnosis of carbamoyl phosphate synthetase I deficiency by identification of a missense mutation in CPS1. Hum Mutat (1998) 0.99
Segmental differences in electrical properties and Na-transport of rabbit caecum, proximal and distal colon in vitro. Pflugers Arch (1985) 0.99
Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut (1985) 0.98
Development of methods for evaluating toxicity to freshwater ecosystems. Ecotoxicol Environ Saf (2000) 0.97
A new approach to determine the genetic diversity of viable and active bacteria in aquatic ecosystems. Cytometry (2001) 0.97
Distinction of nephroblastomas from other childhood tumors using antibodies to intermediate filaments. Virchows Arch B Cell Pathol Incl Mol Pathol (1984) 0.96
Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res (1986) 0.96
Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch (2001) 0.96
Autocrine stimulation of human pancreatic duct-like development by soluble isoforms of epimorphin in vitro. J Cell Biol (2001) 0.96
Association and linkage of allelic variants of the dopamine transporter gene in ADHD. Mol Psychiatry (2007) 0.96
Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal (2008) 0.95
Functional disruption of IEX-1 expression by concatemeric hammerhead ribozymes alters growth properties of 293 cells. FEBS Lett (2001) 0.95
Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ (2010) 0.95
Treatment of infantile spasms with high-dosage vitamin B6. Epilepsia (1993) 0.94
Pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy: outcome and prognostic factors. Chest (1998) 0.94
The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition. Oncogene (2007) 0.94
Prediction of low body weight at long-term follow-up in acute anorexia nervosa by low body weight at referral. Am J Psychiatry (1997) 0.94
Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol (2002) 0.94
Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines. Pancreas (1988) 0.93
Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer (2006) 0.93
Use of a quantitative TaqMan-PCR for the fast quantification of mycobacteria in broth culture, eukaryotic cell culture and tissue. J Vet Med B Infect Dis Vet Public Health (2003) 0.93
Binge-eating episodes are not characteristic of carriers of melanocortin-4 receptor gene mutations. Mol Psychiatry (2004) 0.93
Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene (2006) 0.93